Delayed clot removal improves recovery in stroke patients beyond initial 24-hour window
A large-scale trial across 35 Chinese centers found that mechanical thrombectomy performed between 24 and 72 hours after ischemic stroke significantly improved functional outcomes. Patients who received the procedure were nearly 14% more likely to regain independence at 90 days compared to those receiving only standard medication. The results challenge previous assumptions about time limits for effective clot removal.
A large-scale randomized trial known as LATE-MT, conducted across 35 stroke centers in China, found that mechanical thrombectomy performed between 24 and 72 hours after symptom onset significantly improved functional recovery in patients with acute ischemic stroke caused by large vessel occlusion. The study included 336 adult participants, evenly divided into two groups: one receiving standard medical care alone (antiplatelets, edema management, and supportive treatment), and the other undergoing thrombectomy within 60 minutes of randomization, with procedures occurring between 24 and 72 hours post-stroke. At 90 days, 49% of thrombectomy patients achieved independence in daily activities—compared to 35% in the control group—and 26.9% had minimal disability on the modified Rankin Scale, versus 15.6% in the medication-only group. The results were published in the New England Journal of Medicine in 2026 (DOI: 10.1056/nejmoa2609362). Despite these gains, thrombectomy was associated with a higher risk of symptomatic intracranial hemorrhage (4.8%) and a 90-day mortality rate of 6.0%, compared to 1.8% in the control group.
Prior to this trial, mechanical thrombectomy had been firmly established as effective only within the first 24 hours after stroke onset, based on earlier landmark studies like DEFUSE-3 and DAWN, which set time-based eligibility criteria. The LATE-MT study challenged that consensus by demonstrating benefit beyond the traditional window, provided salvageable brai
The LATE-MT trial could reshape stroke care globally by challenging long-standing time-based exclusion criteria for mechanical thrombectomy. Patients who arrive at hospitals beyond 24 hours—common due to delayed symptom recognition or geographic barriers—may now have a renewed chance at meaningful recovery, potentially reducing long-term disability and healthcare burden. This shift may prompt changes in emergency protocols, increase demand for advanced imaging like perfusion MRI or CT perfusion, and influence insurance coverage policies. Hospitals may need to invest in neurointerventional capabilities and staffing to support extended treatment windows. The trial’s findings echo the impact of earlier studies such as DAWN and DEFUSE-3, which similarly expanded eligibility based on imaging rather than time alone—though LATE-MT is notable for its focus on a broader, non-Western population. The societal implications extend beyond individual patients: caregivers may experience reduced str